Mitigated Patent Risks, Strong Pipeline Bode Well for Merck (MRK) - Cramer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Merck (MRK) NDA for NOXAFIL Accepted by FDA
April 10, 2013 8:33 AM EDTMerck (NYSE: MRK) announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).
Merck currently markets NOXAFIL Oral Suspension for prophylaxis... More
Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)
April 10, 2013 8:30 AM EDTJefferies boosted its price targets on a host of pharmaceuticals stocks into Q1 earnings season. The firm is positive on the sector and sees valuation as attractive for most stocks.
The firm's top pick in the US is AbbVie, with Novartis being their most preferred name in Europe.... More
